Türeci Ö - Search Results

1

Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.

Gayed J, Diya O, Lowry FS, Xu X, Bangad V, Mensa F, Zou J, Xie X, Hu Y, Lu C, Cutler M, Belanger T, Cooper D, Koury K, Anderson AS, Türeci Ö, Şahin U, Swanson KA, Modjarrad K, Gurtman A, Kitchin N; C4591054 Study Group. Gayed J, et al. Among authors: tureci o. Vaccines (Basel). 2024 Jan 24;12(2):118. doi: 10.3390/vaccines12020118. Vaccines (Basel). 2024. PMID: 38400102 Free PMC article.

2

Identification of tumor-associated autoantigens with SEREX.

Türeci O, Usener D, Schneider S, Sahin U. Türeci O, et al. Methods Mol Med. 2005;109:137-54. doi: 10.1385/1-59259-862-5:137. Methods Mol Med. 2005. PMID: 15585919

3

The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes.

Koslowski M, Sahin U, Huber C, Türeci O. Koslowski M, et al. Among authors: tureci o. Hum Mol Genet. 2006 Aug 1;15(15):2392-9. doi: 10.1093/hmg/ddl163. Epub 2006 Jun 29. Hum Mol Genet. 2006. PMID: 16809397

4

Selective activation of tumor growth-promoting Ca2+ channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2.

Koslowski M, Türeci O, Huber C, Sahin U. Koslowski M, et al. Among authors: tureci o. Mol Cancer. 2009 Sep 25;8:77. doi: 10.1186/1476-4598-8-77. Mol Cancer. 2009. PMID: 19781065 Free PMC article.

5

Tumor vaccination using messenger RNA: prospects of a future therapy.

Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. Kreiter S, et al. Among authors: tureci o. Curr Opin Immunol. 2011 Jun;23(3):399-406. doi: 10.1016/j.coi.2011.03.007. Epub 2011 Apr 13. Curr Opin Immunol. 2011. PMID: 21497074 Review.

6

Targeting the tumor mutanome for personalized vaccination therapy.

Kreiter S, Castle JC, Türeci O, Sahin U. Kreiter S, et al. Among authors: tureci o. Oncoimmunology. 2012 Aug 1;1(5):768-769. doi: 10.4161/onci.19727. Oncoimmunology. 2012. PMID: 22934277 Free PMC article.

7

Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies.

Diken M, Kreiter S, Selmi A, Türeci O, Sahin U. Diken M, et al. Among authors: tureci o. Methods Mol Biol. 2013;969:235-46. doi: 10.1007/978-1-62703-260-5_15. Methods Mol Biol. 2013. PMID: 23296938 Review.

8

Antigen identification using SEREX.

Sahin U, Türeci O. Sahin U, et al. Among authors: tureci o. Methods Mol Biol. 2013;1061:59-77. doi: 10.1007/978-1-62703-589-7_3. Methods Mol Biol. 2013. PMID: 23963930

9

mRNA-based therapeutics--developing a new class of drugs.

Sahin U, Karikó K, Türeci Ö. Sahin U, et al. Among authors: tureci o. Nat Rev Drug Discov. 2014 Oct;13(10):759-80. doi: 10.1038/nrd4278. Epub 2014 Sep 19. Nat Rev Drug Discov. 2014. PMID: 25233993 Review.

10

Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies.

Omokoko T, Simon P, Türeci Ö, Sahin U. Omokoko T, et al. Among authors: tureci o. Oncoimmunology. 2015 Mar 19;4(7):e1005523. doi: 10.1080/2162402X.2015.1005523. eCollection 2015 Jul. Oncoimmunology. 2015. PMID: 26140230 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

193 results

Search Page